# EDGAR Filing Document

**Accession Number:** 0001950105
**File Stem:** 0001193125-23-048858
**Filing Date:** 2023-2
**Character Count:** 13236
**Document Hash:** 29889030f38df5edf313910597ffbc0a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-048858.hdr.sgml**: 20230224

**ACCESSION NUMBER**: 0001193125-23-048858

**CONFORMED SUBMISSION TYPE**: SC 13G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230224

**DATE AS OF CHANGE**: 20230224

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Disc Medicine, Inc.
- **CENTRAL INDEX KEY:** 0001816736
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 851613057
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91633
- **FILM NUMBER:** 23668145

**BUSINESS ADDRESS:**
- **STREET 1:** 300 ONE KENDALL SQUARE, 3RD FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139
- **BUSINESS PHONE:** (617) 401-4400

**MAIL ADDRESS:**
- **STREET 1:** 300 ONE KENDALL SQUARE, 3RD FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Gemini Therapeutics, Inc. /DE
- **DATE OF NAME CHANGE:** 20210209

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FS Development Corp.
- **DATE OF NAME CHANGE:** 20200702
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Bain Capital Life Sciences Opportunities III, LP
- **CENTRAL INDEX KEY:** 0001950105
- **IRS NUMBER:** 871325992
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G

**BUSINESS ADDRESS:**
- **STREET 1:** 200 CLARENDON STREET
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
- **BUSINESS PHONE:** 6175162000

**MAIL ADDRESS:**
- **STREET 1:** 200 CLARENDON STREET
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116

------

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, DC 20549** 

------

**SCHEDULE 13G** 

**(Rule 13d-102)** 

**Information to be Included in Statements Filed Pursuant** 

**to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed** 

**Pursuant to § 240.13d-2** 

**Under the Securities Exchange Act of 1934** 

**(Amendment No.)** 

------

## Disc Medicine, Inc.
**(Name of Issuer)** 

**Common Stock, $0.0001** 

**par value per share** 

**(Title of Class of Securities)** 

**254604101** 

**(CUSIP Number)** 

**February 15, 2023** 

**(Date of Event Which Requires Filing of This Statement)** 

------

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended ("Act"), or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

------

CUSIP No. 254604101 13G Page 2 of 6

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp; 1 | &nbsp;&nbsp;&nbsp;&nbsp;Names of reporting persons<br>&nbsp;&nbsp;&nbsp;&nbsp;Bain Capital Life Sciences Opportunities III, LP |
| &nbsp;&nbsp;&nbsp; 2 | &nbsp;&nbsp;&nbsp;&nbsp;Check the appropriate box if a member of a group<br> &nbsp;&nbsp;&nbsp;&nbsp;(a) ☐ (b) ☐ |
| &nbsp;&nbsp;&nbsp; 3 | &nbsp;&nbsp;&nbsp;&nbsp;SEC use only |
| &nbsp;&nbsp;&nbsp; 4 | &nbsp;&nbsp;&nbsp;&nbsp;Citizenship or place of organization<br>&nbsp;&nbsp;&nbsp;&nbsp;Delaware |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp; Number of<br> shares<br> beneficially <br> owned by<br> each<br> reporting<br> person<br> with: | 5 | &nbsp;&nbsp;&nbsp;&nbsp;Sole voting power<br>&nbsp;&nbsp;&nbsp;&nbsp;0 shares of Common Stock |
| &nbsp;&nbsp;&nbsp; Number of<br> shares<br> beneficially <br> owned by<br> each<br> reporting<br> person<br> with: | 6 | &nbsp;&nbsp;&nbsp;&nbsp;Shared voting power<br>&nbsp;&nbsp;&nbsp;&nbsp;1,990,914 shares of Common Stock (1) |
| &nbsp;&nbsp;&nbsp; Number of<br> shares<br> beneficially <br> owned by<br> each<br> reporting<br> person<br> with: | 7 | &nbsp;&nbsp;&nbsp;&nbsp;Sole dispositive power<br>&nbsp;&nbsp;&nbsp;&nbsp;0 shares of Common Stock |
| &nbsp;&nbsp;&nbsp; Number of<br> shares<br> beneficially <br> owned by<br> each<br> reporting<br> person<br> with: | 8 | &nbsp;&nbsp;&nbsp;&nbsp;Shared dispositive power<br>&nbsp;&nbsp;&nbsp;&nbsp;1,990,914 shares of Common Stock (1) |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp; 9 | &nbsp;&nbsp;&nbsp;&nbsp;Aggregate amount beneficially owned by each reporting person<br>&nbsp;&nbsp;&nbsp;&nbsp;1,990,914 shares of Common Stock (1) |
| &nbsp;&nbsp;&nbsp;10 | &nbsp;&nbsp;&nbsp;&nbsp;Check if the aggregate amount in Row (9) excludes certain shares<br>&nbsp;&nbsp;&nbsp;&nbsp;☐ |
| &nbsp;&nbsp;&nbsp;11 | &nbsp;&nbsp;&nbsp;&nbsp;Percent of class represented by amount in Row (9)<br>&nbsp;&nbsp;&nbsp;&nbsp;9.99% (1) |
| &nbsp;&nbsp;&nbsp;12 | &nbsp;&nbsp;&nbsp;&nbsp;Type of reporting person<br>&nbsp;&nbsp;&nbsp;&nbsp;PN |

---

(1) As of the date hereof, Bain Capital Life Sciences Opportunities III, LP holds 944,687 shares of Common Stock
and pre-funded warrants to purchase 1,229,224 shares of Common Stock. As a result of the Beneficial Ownership Blocker (as defined herein), beneficial ownership of Bain Capital Life Sciences Opportunities III,
LP is capped at 9.99% of the outstanding shares of Common Stock, representing 1,990,914 shares of Common Stock calculated as described herein as of the date hereof.

The calculation of beneficial ownership is based on (i) 18,882,850 shares of Common Stock issued and outstanding, as reported by the Issuer in its prospectus supplement filed with the Securities and Exchange Commission on February 14, 2023 and (ii) 1,046,227 shares of Common Stock to be issued upon the exercise of pre-funded warrants held by Bain Capital Life Sciences Opportunities III, LP, which reflects the Beneficial Ownership Blocker.

------

CUSIP No. 254604101 13G Page 3 of 6

**Item 1(a). Name of Issuer** 

The name of the issuer to which this filing on Schedule 13G relates is Disc Medicine, Inc. (the "Issuer").

**Item 1(b). Address of Issuer's Principal Executive Offices** 

The principal executive offices of the Issuer are located at 321 Arsenal Street, Suite 101, Watertown, Massachusetts 02472.

**Item 2(a). Name of Person Filing** 

This Schedule 13G is being filed by Bain Capital Life Sciences Opportunities III, LP, a Delaware limited partnership (the "Reporting Person").

Bain Capital Life Sciences Investors, LLC, a Delaware limited liability company ("BCLSI"), is the manager of Bain Capital Life Sciences III General Partner, LLC, a Delaware limited liability company ("BCLS Fund III GP"), which is the general partner of Bain Capital Life Sciences Fund III, L.P., a Delaware limited partnership ("BCLS Fund III"), which is the sole member of Bain Capital Life Sciences Opportunities III GP, LLC, a Delaware limited liability company ("BCLS III Opportunities GP" and, together with the Reporting Person, BCLSI, BCLS Fund III GP and BCLS Fund III, the "Bain Capital Life Sciences Entities"), which is the general partner of the Reporting Person. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the securities held by the Reporting Person.

**Item 2(b). Address of Principal Business Office or, if None, Residence** 

The principal business address for each of the Bain Capital Life Sciences Entities is 200 Clarendon Street, Boston, Massachusetts 02116.

**Item 2(c). Citizenship** 

Each of the Bain Capital Life Sciences Entities are organized under the laws of the State of Delaware.

**Item 2(d). Title of Class of Securities** 

The class of securities of the Issuer to which this Schedule 13G relates is Common Stock, $0.0001 par value per share ("Common Stock").

**Item 2(e). CUSIP Number** 

The CUSIP number of the Common Stock is 254604101.

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a** 

---

| | | |
|:---|:---|:---|
| (a) | ☐ | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); |
| (b) | ☐ | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); |
| (c) | ☐ | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); |
| (d) | ☐ | Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); |
| (e) | ☐ | An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E); |
| (f) | ☐ | An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F); |

---

------

CUSIP No. 254604101 13G Page 4 of 6

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12
U.S.C. 1813);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14)
of the Investment Company Act (15 U.S.C. 80a-3);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k) ☐ Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution.

**Item 4. Ownership** 

**(a) Amount beneficially owned:** 

As of the date hereof, the Reporting Person holds 944,687 shares of Common Stock and pre-funded warrants to purchase 1,229,224 shares of Common Stock.

The Reporting Person is prohibited from exercising its pre-funded warrants if, as a result of such exercise, the Reporting Person would beneficially own more than 9.99% of the total number of shares of Common Stock then issued and outstanding immediately after giving effect to the exercise (the "Beneficial Ownership Blocker"). Accordingly, pursuant to Rule 13d-3 of the Act and the relationships described herein, the Reporting Person may be deemed to beneficially own 9.99% of the outstanding shares of Common Stock, representing 1,990,914 shares of Common Stock as of the date hereof.

The calculation of beneficial ownership is based on (i) 18,882,850 shares of Common Stock issued and outstanding, as reported by the Issuer in its prospectus supplement filed with the Securities and Exchange Commission on February 14, 2023 and (ii) 1,046,227 shares of Common Stock to be issued upon the exercise of pre-funded warrants held by the Reporting Person, which reflects the Beneficial Ownership Blocker.

**(b) Percent of class:** 

See Item 4(a) hereof.

**(c) Number of shares as to which the person has:** 

(i) Sole power to vote or to direct the vote:

(ii) Shared power to vote or direct the vote:

See Item 4(a) hereof

(iii) Sole power to dispose or to direct the disposition of:

(iv) Shared power to dispose or to direct the disposition of:

See Item 4(a) hereof

------

CUSIP No. 254604101 13G Page 5 of 6

**Item 5. Ownership of Five Percent or Less of a Class** 

Not applicable.

**Item 6. Ownership of More than Five Percent on Behalf of Another Person** 

Not applicable.

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person** 

Not applicable.

**Item 8. Identification and Classification of Members of the Group** 

Not applicable.

**Item 9. Notice of Dissolution of Group** 

Not applicable.

**Item 10. Certifications** 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

------

CUSIP No. 254604101 13G Page 6 of 6

**SIGNATURES** 

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information in this statement is true, complete and correct.

---

| | | |
|:---|:---|:---|
| Dated: February 24, 2023 | **Bain Capital Life Sciences Opportunities III, LP** | **Bain Capital Life Sciences Opportunities III, LP** |
|  | By: | Bain Capital Life Sciences Opportunities III GP, LLC, |
|  |  | its general partner |
|  | By: | Bain Capital Life Sciences Fund III, L.P., |
|  |  | its sole member |
|  | By: | Bain Capital Life Sciences III General Partner, LLC, |
|  |  | its general partner |
|  | By: | Bain Capital Life Sciences Investors, LLC, |
|  |  | its manager |
|  | By: | /s/ Ricky Sun |
|  |  | Name: Ricky Sun |
|  |  | Title: Partner |

---